Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study
- 1 January 1997
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 51 (5) , 395-398
- https://doi.org/10.1007/s002280050220
Abstract
The clinical relevance of the CYP2D6 oxidation polymorphism in the treatment of depression with desipramine (DMI) was studied prospectively in depressed outpatients.Keywords
This publication has 24 references indexed in Scilit:
- Polymorphic Drug OxidationCNS Drugs, 1996
- CYP2D6-related oxidation polymorphism in ItalyPharmacological Research, 1994
- Pharmacogenetic aspects in the metabolism of psychotropic drugs: Pharmacokinetic and clinical implicationsPharmacological Research, 1994
- Genetically variable metabolism of antidepressants and neuroleptic drugs in manPharmacogenetics, 1993
- Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquineThe Lancet, 1993
- Importance of Oxidative Polymorphism on Clinical Efficacy and Side-Effects of Imipramine - A Retrospective StudyPharmacopsychiatry, 1988
- Urinary Desipramine Hydroxylation Index and Steady-State Plasma Concentrations of Imipramine and DesipramineTherapeutic Drug Monitoring, 1987
- SLOW HYDROXYLATION OF NORTRIPTYLINE AND CONCOMITANT POOR DEBRISOQUINE HYDROXYLATION: CLINICAL IMPLICATIONSThe Lancet, 1981
- High‐Performance Liquid Chromatographic Assay for Imipramine, Desipramine, and Their 2‐Hydroxylated MetabolitesJournal of Pharmaceutical Sciences, 1979
- Benzodiazepines and Tricyclic Antidepressant Plasma LevelsBMJ, 1973